Literature DB >> 24510580

Modulation of the renin-angiotensin-aldosterone system in heart failure.

J George1, A D Struthers, C C Lang.   

Abstract

The renin-angiotensin-aldosterone system (RAAS) is well-established and continues to be pursued as a therapeutic target in the treatment of heart failure, predominantly due to the success of agents that block RAAS in clinical trials of systolic heart failure. The optimal treatment of heart failure patients with preserved ejection fraction (HFpEF), however, remains unclear. Early trials of direct renin inhibitors have suggested that these agents may play a role in HFpEF, but recent clinical trial results have not been encouraging. Preliminary trials of angiotensin-receptor/neprilysin inhibitors look promising. Whether results with these or other drugs will alter current recommendations remains to be seen. In this review, we assess the current understanding of the role of RAAS modulation in heart failure.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24510580     DOI： 10.1007/s11883-014-0403-7

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


  64 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.

Authors:  Joep H M van Esch; Els Moltzer; Richard van Veghel; Ingrid M Garrelds; Frank Leijten; Angelique M Bouhuizen; A H Jan Danser
Journal:  J Hypertens       Date:  2010-10       Impact factor: 4.844

3.  Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.

Authors:  M A Konstam; M F Rousseau; M W Kronenberg; J E Udelson; J Melin; D Stewart; N Dolan; T R Edens; S Ahn; D Kinan
Journal:  Circulation       Date:  1992-08       Impact factor: 29.690

4.  Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.

Authors:  Henry Krum; Barry Massie; William T Abraham; Kenneth Dickstein; Lars Kober; John J V McMurray; Ashkay Desai; Claudio Gimpelewicz; Albert Kandra; Bernard Reimund; Henning Rattunde; Juergen Armbrecht
Journal:  Eur J Heart Fail       Date:  2011-01       Impact factor: 15.534

5.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.

Authors:  J L Rouleau; M A Pfeffer; D J Stewart; D Isaac; F Sestier; E K Kerut; C B Porter; G Proulx; C Qian; A J Block
Journal:  Lancet       Date:  2000-08-19       Impact factor: 79.321

6.  How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?

Authors:  R J MacFadyen; A F Lee; J J Morton; S D Pringle; A D Struthers
Journal:  Heart       Date:  1999-07       Impact factor: 5.994

7.  Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

Authors:  Jessie Gu; Adele Noe; Priya Chandra; Suliman Al-Fayoumi; Monica Ligueros-Saylan; Ramesh Sarangapani; Suzanne Maahs; Gary Ksander; Dean F Rigel; Arco Y Jeng; Tsu-Han Lin; Weiyi Zheng; William P Dole
Journal:  J Clin Pharmacol       Date:  2009-11-23       Impact factor: 3.126

8.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

Review 9.  Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.

Authors:  John J V McMurray; William T Abraham; Kenneth Dickstein; Lars Køber; Barry M Massie; Henry Krum
Journal:  Eur J Heart Fail       Date:  2012-04       Impact factor: 15.534

10.  (Pro)renin receptor triggers distinct angiotensin II-independent extracellular matrix remodeling and deterioration of cardiac function.

Authors:  Anne-Mari Moilanen; Jaana Rysä; Raisa Serpi; Erja Mustonen; Zoltán Szabò; Jani Aro; Juha Näpänkangas; Olli Tenhunen; Meeri Sutinen; Tuula Salo; Heikki Ruskoaho
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240
View more
  4 in total

Review 1.  Biomarkers of Volume Overload and Edema in Heart Failure With Reduced Ejection Fraction.

Authors:  Roxana Mihaela Chiorescu; Roxana-Daiana Lazar; Sándor-Botond Buksa; Mihaela Mocan; Dan Blendea
Journal:  Front Cardiovasc Med       Date:  2022-06-17

2.  Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival.

Authors:  Ryan D Sullivan; Radhika M Mehta; Ranjana Tripathi; Inna P Gladysheva; Guy L Reed
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

3.  QiShenYiQi pill activates autophagy to attenuate reactive myocardial fibrosis via the PI3K/AKT/mTOR pathway.

Authors:  Shichao Lv; Peng Yuan; Chunmiao Lu; Jianping Dong; Meng Li; Fan Qu; Yaping Zhu; Junping Zhang
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

4.  Effect of Traditional Chinese Medicine Poge Heart-Saving Decoction on Cardiac Function in Heart Failure Rat Model.

Authors:  Lei Liu; Yanfei Mo; Bingying Wu; Zongliang Yu; Bugao Sun
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-03       Impact factor: 2.629
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.